Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate
Aura Biosciences Inc (NASDAQ:AURA) announced the presentation of interim Phase 2 safety and efficacy data of belzupacap sarotalocan (bel-sar;…
$49.5 Million Bet On Howard Hughes? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mostly lower on Wednesday, there were a few notable insider trades.
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24.
Vapotherm, Inc. (NASDAQ: VAPO) gained 48.8% to $1.3250.
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Vapotherm (NYSE:VAPO) shares rose 44.2% to $1.28 during Thursday’s regular session. As of 12:30 EST, this security…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Otonomy (NASDAQ:OTIC) shares increased by 19.1% to $0.21 during Thursday’s pre-market session. The company’s market cap stands…
Reported Late Wednesday, Aura Biosciences Announces Pricing Of $80.4M Public Offering Of 6.7M Shares Of Common Stock At A Price Of $12/Share
Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 236 companies set new 52-week lows.
Tesla, ABB And Other Big Losers From Monday
U.S. stocks closed sharply higher with the Dow Jones jumping more than 750 points on Monday. Here is the list of some big stocks recording losses in the previous session.
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug
Aura Biosciences Inc (NASDAQ:AURA) detailed interim data from its ongoing Phase 2 trial of an eye cancer drug, elzupacap sarotalocan (AU‑011).…